Characterizing the cross-sectional approach to investigate the prevalence of tissue BRCA1/2 mutations in newly diagnosed advanced ovarian cancer patients - CHRISTELLE

Study identifier:D0817R00018

ClinicalTrials.gov identifier:NCT04222465

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Characterizing the cross-sectional approach to investigate the prevalence of tissue BRCA1/2 mutations in newly diagnosed advanced ovarian cancer patients

Medical condition

ovarian neoplasms

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

Female

Actual enrollment

207

Study type

Observational

Age

20 Years +

Date

Study Start Date: 19 Mar 2020
Primary Completion Date: 13 Nov 2020
Study Completion Date: 13 Nov 2020

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria